TNFα is involved in neuropathic pain induced by nucleoside reverse transcriptase inhibitor in rats

Brain, Behavior, and Immunity

Volumn 25, Issue 8, 2011, Pages 1668-1676

  Zheng, Xuexing ^a,b   Ouyang, Handong ^c,d   Liu, Shue ^a   Mata, Marina ^c   Fink, David J ^c   Hao, Shuanglin ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JILIN UNIVERSITY   (China)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

DdC; HIV; Neuropathic pain; TNF

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; MESSENGER RNA; NEURON SPECIFIC NUCLEAR PROTEIN; RECOMBINANT RECEPTOR; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; ZALCITABINE;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; MALE; NEUROPATHIC PAIN; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; RNA INTERFERENCE; SPINAL CORD DORSAL HORN;

ANALGESICS; ANIMALS; ANTIGENS, NUCLEAR; BLOTTING, WESTERN; GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOHISTOCHEMISTRY; INJECTIONS, SPINAL; MALE; NERVE TISSUE PROTEINS; NEURALGIA; PAIN THRESHOLD; PENTOXIFYLLINE; PHYSICAL STIMULATION; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, SMALL INTERFERING; SPINAL CORD; TUMOR NECROSIS FACTOR-ALPHA; ZALCITABINE;

EID: 80053896545     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2011.06.010     Document Type: Article

References (64)

1. Arenas-Pinto A., Bhaskaran K., Dunn D., Weller I.V. The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial. Antivir. Ther. 2008, 13:289-295.
2. Beck E.J., Mandalia S., Williams I., Power A., Newson R., Molesworth A., Barlow D., Easterbrook P., Fisher M., Innes J., Kinghorn G., Mandel B., Pozniak A., Tang A., Tomlinson D. Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. National prospective monitoring system steering group. AIDS 1999, 13:2157-2164.
3. Berger A.R., Arezzo J.C., Schaumburg H.H., Skowron G., Merigan T., Bozzette S., Richman D., Soo W. 2',3'-Dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology 1993, 43:358-362.
4. Bhangoo S.K., Ren D., Miller R.J., Chan D.M., Ripsch M.S., Weiss C., McGinnis C., White F.A. CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy. Brain Behav. Immun. 2007, 21:581-591.
5. Chaplan S.R., Bach F.W., Pogrel J.W., Chung J.M., Yaksh T.L. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 1994, 53:55-63.
6. Cheepsunthorn P., Radov L., Menzies S., Reid J., Connor J.R. Characterization of a novel brain-derived microglial cell line isolated from neonatal rat brain. Glia 2001, 35:53-62.
7. Choi H.C., Song P., Xie Z., Wu Y., Xu J., Zhang M., Dong Y., Wang S., Lau K., Zou M.H. Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo. J. Biol. Chem. 2008, 283:20186-20197.
8. Costigan M., Scholz J., Woolf C.J. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu. Rev. Neurosci. 2009, 32:1-32.
9. Cui Y., Liao X.X., Liu W., Guo R.X., Wu Z.Z., Zhao C.M., Chen P.X., Feng J.Q. A novel role of minocycline: attenuating morphine antinociceptive tolerance by inhibition of p38 MAPK in the activated spinal microglia. Brain Behav. Immun. 2008, 22:114-123.
10. Dalakas M.C. Peripheral neuropathy and antiretroviral drugs. J. Peripher. Nerv. Syst. 2001, 6:14-20.
11. Dalakas M.C., Semino-Mora C., Leon-Monzon M. Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC). Lab. Invest. 2001, 81:1537-1544.
12. DeLeo J.A., Colburn R.W., Rickman A.J. Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy. Brain Res. 1997, 759:50-57.
13. DeLeo J.A., Rutkowski M.D., Stalder A.K., Campbell I.L. Transgenic expression of TNF by astrocytes increases mechanical allodynia in a mouse neuropathy model. NeuroReport 2000, 11:599-602.
14. DeLeo J.A., Tanga F.Y., Tawfik V.L. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist 2004, 10:40-52.
15. Dixon W.J. Efficient analysis of experimental observations. Annu. Rev. Pharmacol. Toxicol. 1980, 20:441-462.
16. Dorsey S.G., Morton P.G. HIV peripheral neuropathy: pathophysiology and clinical implications. AACN Clin. Issues 2006, 17:30-36.
17. Dubinsky R.M., Yarchoan R., Dalakas M., Broder S. Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2',3'-dideoxycytidine (ddC). Muscle Nerve 1989, 12:856-860.
18. Gao Y.J., Zhang L., Samad O.A., Suter M.R., Yasuhiko K., Xu Z.Z., Park J.Y., Lind A.L., Ma Q., Ji R.R. JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J. Neurosci. 2009, 29:4096-4108.
19. Haas D.W., Geraghty D.E., Andersen J., Mar J., Motsinger A.A., D'Aquila R.T., Unutmaz D., Benson C.A., Ritchie M.D., Landay A. Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: an AIDS clinical trials group study. J. Infect. Dis. 2006, 194:1098-1107.
20. Hao S., Mata M., Fink D.J. Viral vector-based gene transfer for treatment of chronic pain. Int. Anesthesiol. Clin. 2007, 45:59-71.
21. Hao S., Mata M., Glorioso J.C., Fink D.J. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther. 2007, 14:1010-1016.
22. Hao S., Wolfe D., Glorioso J.C., Mata M., Fink D.J. Effects of transgene-mediated endomorphin-2 in inflammatory pain. Eur. J. Pain 2009, 13:380-386.
23. Hao S., Liu S., Zheng X., Zheng W., Ouyang H., Mata M., Fink D.J. The role of TNFalpha in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats. Neuropsychopharmacology 2011, 36:664-676.
24. Hashizume H., DeLeo J.A., Colburn R.W., Weinstein J.N. Spinal glial activation and cytokine expression after lumbar root injury in the rat. Spine (Phila Pa 1976) 2000, 25:1206-1217.
25. He X.H., Zang Y., Chen X., Pang R.P., Xu J.T., Zhou X., Wei X.H., Li Y.Y., Xin W.J., Qin Z.H., Liu X.G. TNF-alpha contributes to up-regulation of Nav1.3 and Nav1.8 in DRG neurons following motor fiber injury. Pain 2010, 151:266-279.
26. Homma Y., Brull S.J., Zhang J.M. A comparison of chronic pain behavior following local application of tumor necrosis factor alpha to the normal and mechanically compressed lumbar ganglia in the rat. Pain 2002, 95:239-246.
27. Joseph E.K., Levine J.D. Mitochondrial electron transport in models of neuropathic and inflammatory pain. Pain 2006, 121:105-114.
28. Joseph E.K., Chen X., Khasar S.G., Levine J.D. Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat. Pain 2004, 107:147-158.
29. Kakuda T.N. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 2000, 22:685-708.
30. Keswani S.C., Polley M., Pardo C.A., Griffin J.W., McArthur J.C., Hoke A. Schwann cell chemokine receptors mediate HIV-1 gp120 toxicity to sensory neurons. Ann. Neurol. 2003, 54:287-296.
31. Lewis W., Day B.J., Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug. Discov. 2003, 2:812-822.
32. Lopez O.L., Becker J.T., Dew M.A., Caldararo R. Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS. Eur. J. Neurol. 2004, 11:97-102.
33. Luciano C.A., Pardo C.A., McArthur J.C. Recent developments in the HIV neuropathies. Curr. Opin. Neurol. 2003, 16:403-409.
34. Marchand F., Perretti M., McMahon S.B. Role of the immune system in chronic pain. Nat. Rev. Neurosci. 2005, 6:521-532.
35. Mattioli B., Giordani L., Quaranta M.G., Viora M. Effect of indinavir used alone or in double or triple combination with AZT and ddC on human immune functions. Life Sci. 2004, 74:2291-2300.
36. McCarthy W.F., Gable J., Lawrence J., Thompson M. A retrospective study to determine if hydroxyurea augmentation of antiretroviral drug regimens that contain ddI and/or d4T increases the risk of developing peripheral neuropathy in HIV-1 infected individuals. Pharmacoepidemiol. Drug Saf. 2000, 9:49-53.
37. Mika J., Osikowicz M., Rojewska E., Korostynski M., Wawrzczak-Bargiela A., Przewlocki R., Przewlocka B. Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain. Eur. J. Pharmacol. 2009, 623:65-72.
38. Muscoli C., Cuzzocrea S., Ndengele M.M., Mollace V., Porreca F., Fabrizi F., Esposito E., Masini E., Matuschak G.M., Salvemini D. Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice. J. Clin. Invest. 2007, 117:3530-3539.
39. Newshan G. Pain in human immunodeficiency virus disease. Semin. Oncol. Nurs. 1997, 13:36-41.
40. Opii W.O., Sultana R., Abdul H.M., Ansari M.A., Nath A., Butterfield D.A. Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)-2',3'-dideoxycytidine (ddC): relevance to HIV-dementia. Exp. Neurol. 2007, 204:29-38.
41. Pardo C.A., McArthur J.C., Griffin J.W. HIV neuropathy: insights in the pathology of HIV peripheral nerve disease. J. Peripher. Nerv. Syst. 2001, 6:21-27.
42. Peng X.M., Zhou Z.G., Glorioso J.C., Fink D.J., Mata M. Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann. Neurol. 2006, 59:843-851.
43. Raghavendra V., Rutkowski M.D., DeLeo J.A. The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J. Neurosci. 2002, 22:9980-9989.
44. Reliquet V., Mussini J.M., Chennebault J.M., Lafeuillade A., Raffi F. Peripheral neuropathy during stavudine-didanosine antiretroviral therapy. HIV Med. 2001, 2:92-96.
45. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J. Neurovirol. 2002, 8(Suppl. 2):115-121.
46. Saito O., Svensson C.I., Buczynski M.W., Wegner K., Hua X.Y., Codeluppi S., Schaloske R.H., Deems R.A., Dennis E.A., Yaksh T.L. Spinal glial TLR4-mediated nociception and production of prostaglandin E(2) and TNF. Br. J. Pharmacol. 2010, 160:1754-1764.
47. Schafers M., Svensson C.I., Sommer C., Sorkin L.S. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J. Neurosci. 2003, 23:2517-2521.
48. Schifitto G., McDermott M.P., McArthur J.C., Marder K., Sacktor N., Epstein L., Kieburtz K. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002, 58:1764-1768.
49. Shohami E., Bass R., Wallach D., Yamin A., Gallily R. Inhibition of tumor necrosis factor alpha (TNFalpha) activity in rat brain is associated with cerebroprotection after closed head injury. J. Cereb. Blood Flow Metab. 1996, 16:378-384.
50. Simpson D.M. Selected peripheral neuropathies associated with human immunodeficiency virus infection and antiretroviral therapy. J Neurovirol 2002, 8(Suppl. 2):33-41.
51. Simpson D.M., Kitch D., Evans S.R., McArthur J.C., Asmuth D.M., Cohen B., Goodkin K., Gerschenson M., So Y., Marra C.M., Diaz-Arrastia R., Shriver S., Millar L., Clifford D.B. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology 2006, 66:1679-1687.
52. Sommer C., Schmidt C., George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp. Neurol. 1998, 151:138-142.
53. Sun J., Liu S., Mata M., Fink D.J., Hao S. Transgene-mediated expression of tumor necrosis factor soluble receptor attenuates morphine tolerance in rats. Gene Ther. 2011, [Epub ahead of print].
54. Svensson C.I., Schafers M., Jones T.L., Powell H., Sorkin L.S. Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci. Lett. 2005, 379:209-213.
55. Sweitzer S., Martin D., DeLeo J.A. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience 2001, 103:529-539.
56. Sweitzer S.M., Schubert P., DeLeo J.A. Propentofylline, a glial modulating agent, exhibits antiallodynic properties in a rat model of neuropathic pain. J. Pharmacol. Exp. Ther. 2001, 297:1210-1217.
57. Szewczyk A., Wojtczak L. Mitochondria as a pharmacological target. Pharmacol. Rev. 2002, 54:101-127.
58. Tan P.H., Yang L.C., Shih H.C., Lan K.C., Cheng J.T. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther. 2005, 12:59-66.
59. Wallace V.C., Blackbeard J., Segerdahl A.R., Hasnie F., Pheby T., McMahon S.B., Rice A.S. Characterization of rodent models of HIV-gp120 and anti-retroviral-associated neuropathic pain. Brain 2007, 130:2688-2702.
60. Watkins L.R., Maier S.F. Glia: a novel drug discovery target for clinical pain. Nat. Rev. Drug. Discov. 2003, 2:973-985.
61. Zheng W., Ouyang H., Zheng X., Liu S., Mata M., Fink D.J., Hao S. Glial TNFalpha regulates neuropathic pain induced by HIV gp120 application in rats. Mol. Pain 2011, 7:40.
62. Zhou Z., Peng X., Hao S., Fink D.J., Mata M. HSV-mediated transfer of interleukin-10 reduces inflammatory pain through modulation of membrane tumor necrosis factor alpha in spinal cord microglia. Gene Ther. 2008, 15:183-190.
63. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.
64. Zou W., Kim B.O., Zhou B.Y., Liu Y., Messing A., He J.J. Protection against human immunodeficiency virus type 1 Tat neurotoxicity by Ginkgo biloba extract EGb 761 involving glial fibrillary acidic protein. Am. J. Pathol. 2007, 171:1923-1935.